|Printable version||E-mail this to a friend|
EMA Workshop: working towards new therapies for spinal muscular atrophy
The event will be broadcast live on 11 November
The European Medicines Agency (EMA), Spinal muscular atrophy (SMA) Europe and the TREAT-Neuromuscular diseases (NMD) network are holding a one-day workshop to discuss, support and advance the development of therapies for the treatment of spinal muscular atrophy (SMA). SMA Europe and TREAT-NMD network are two non-profit organisations that bring together patients and academics from Europe and beyond to progress research into SMA and facilitate the development of new therapies.
The workshop will take place at EMA’s premises in London on 11 November 2016, starting at 09:00.
SMA is a rare genetic disease that affects the control of muscle movement. It is caused by a loss of specialised nerve cells, called motor neurons, which results in weakness and wasting (atrophy) of muscles used for activities such as crawling, walking, sitting up, and controlling head movement. Children born with the most serious form of the disease rarely survive beyond the age of two because of severe breathing problems.
At present there is no cure for SMA. Available treatments focus on managing symptoms and preventing complications. However, new therapies are currently being developed and SMA might become one of the first inherited neurological diseases to be successfully treated. A number of experimental therapies are currently being evaluated in early clinical trials and EMA has provided scientific advice to medicine developers on the appropriate tests and studies to be used in the development of medicines for SMA a number of times in the past few years.
The workshop will convene key stakeholders – patients, doctors, industry representatives, researchers and regulators – to take stock of the latest scientific developments in the area and discuss ways of developing therapies for the treatment of SMA. Topics for discussion will include an overview of the disease, the pharmacology of the molecules under investigation, natural history data, clinical outcome measures and potential use of biomarkers in drug development.
- Agenda - EMA - Spinal muscular atrophy workshop (07/11/2016)
Latest News from
Antonio Tajani elected new President of the European Parliament18/01/2017 16:20:00
Antonio Tajani (EPP, IT) won Parliament’s presidential election with 351 votes in a final face-off with Gianni Pittella (S&D, IT), who secured 282 votes.
MAR guidelines on commodity derivatives now available in all EU languages18/01/2017 15:05:00
The European Securities and Markets Authority (ESMA) has issued the official translations of its final guidelines on commodity derivatives under the Market Abuse Regulation (MAR).
EU and US publish TTIP state of play assessment18/01/2017 13:20:00
Trade Commissioner Cecilia Malmström and United States Trade Representative Michael Froman have published a joint assessment of the progress made in the negotiations for a Transatlantic Trade and Investment Partnership (TTIP) since negotiations started in July 2013.
Mid-career reviews key to longer and healthier working lives18/01/2017 11:25:00
Eurofound's new report Changing places: Mid-career review and internal mobility shows that timely mid-career reviews can improve an employee's working life, boost their added value to their employer, and help to address Europe's long-term demographic ageing challenge.
Progress in relations between the EU and Switzerland17/01/2017 15:10:00
Following Switzerland's adoption of the Federal Act on Foreign Nationals on 16 December 2016 and the meeting of the EU-Switzerland Joint Committee on 22 December, the Commission welcomes the progress in EU-Swiss relations in several areas.